Abbvie Inc (ABBV) Stock

Abbvie Inc Stock Details, Movements and Public Alerts

Stock Details

Abbvie Inc (ABBV), a prominent company in the life sciences sector within the pharmaceutical preparations industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $192.84. Over the past 52 weeks, it has ranged between $157.78 and $216.66. This places the current price at 89.0% of its 52-week high and 22.2% above its 52-week low. Recent trading volume was recorded at 407,962. The 14-day Relative Strength Index (RSI) stands at 52.23, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $186.57 by 3.36%. Similarly, it is above its 200-day moving average of $186.42 by 3.44%. The MACD histogram is 0.56, indicating bullish momentum (MACD Line: -0.23, Signal Line: -0.79). There are currently 2 active alerts set for ABBV by users.

52-Week High

$216.66

52-Week Low

$157.78

Volume

407,962

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

79.53

Above market average

Forward P/E

15.31

Earnings expected to grow

PEG Ratio

0.40

Potentially undervalued

Price to Book

231.51

EV/EBITDA

26.55

EPS (TTM)

$2.34

Price to Sales

5.73

Beta

0.55

Less volatile than market

Is ABBV's P/E ratio considered high or low?
Abbvie Inc's current P/E ratio is 79.53, which is above the market average. This typically suggests investors expect higher future growth, or it could mean the stock is relatively expensive compared to its current earnings.
How does ABBV's Forward P/E compare to its current P/E?
Abbvie Inc's current P/E is 79.53 and its Forward P/E is 15.31. The lower Forward P/E suggests analysts expect earnings to grow in the coming year, potentially making the stock more attractively valued based on future earnings.
What does ABBV's PEG ratio tell investors?
Abbvie Inc's PEG ratio is 0.40. A PEG ratio below 1.0 is generally considered favorable and may indicate the stock is undervalued when considering both current earnings and expected growth.
How volatile is ABBV compared to the overall market?
Abbvie Inc's beta value is 0.55. A beta below 1 indicates the stock is less volatile than the market. For example, if the market moves 10%, you might expect this stock to move less than 10%.

Performance & Growth

Profit Margin

7.31%

Operating Margin

30.40%

Return on Equity

88.40%

Return on Assets

8.34%

Revenue Growth (YoY)

8.40%

Earnings Growth (YoY)

-6.30%

How profitable is ABBV compared to its industry peers?
Abbvie Inc has a profit margin of 7.31%. This profit margin is on the lower side. The company is keeping $7.31 in profit for every $100 in sales, which could indicate competitive pressures or cost challenges. Profit margins vary by industry, and PHARMACEUTICAL PREPARATIONS companies typically need to be evaluated against their specific sector benchmarks.
What do ABBV's ROE and ROA figures tell investors?
Abbvie Inc has a Return on Equity (ROE) of 88.40% and a Return on Assets (ROA) of 8.34%. The ROE is strong, indicating efficient use of shareholders' equity to generate profits. The ROA is healthy, suggesting management is effectively using company assets to generate earnings. The large gap between ROE and ROA suggests the company has significant leverage (debt), which amplifies returns but potentially increases risk.
Is ABBV growing faster or slower than in previous periods?
Abbvie Inc's year-over-year quarterly revenue growth is 8.40%. This indicates positive revenue momentum, though at a moderate pace. Meanwhile, earnings growth is -6.30% year-over-year. Earnings are growing slower than revenue, which might indicate increasing costs or investments for future growth. The company is growing its top line while earnings are declining, which could indicate margin pressure or significant investments.
What does ABBV's operating margin tell us about its business model?
Abbvie Inc's operating margin is 30.40%. This is an excellent operating margin that indicates the company has strong pricing power, efficient operations, or both. It suggests a robust business model with good cost control. Operating margins vary widely by industry, and in the pharmaceutical preparations sector, this margin should be evaluated relative to industry peers.

Dividend Information

Dividend Per Share

$6.38

Dividend Yield

3.52%

Ex-Dividend Date

4/15/2025

Dividend Date

5/15/2025

How does ABBV's dividend yield compare to other investments?
Abbvie Inc's dividend yield is currently 3.52%. This yield is above the S&P 500 average (typically around 1.5-2%) and potentially competitive with some fixed-income investments, depending on current interest rates. In the pharmaceutical preparations industry, this yield should be evaluated against industry peers for a meaningful comparison.
What do the ex-dividend and dividend dates mean for ABBV investors?
The next ex-dividend date for Abbvie Inc is 4/15/2025. This is the cut-off date for receiving the upcoming dividend. Investors who purchase shares before this date will receive the dividend, while those who buy on or after this date will not. The actual payment of this dividend will occur on 5/15/2025. The dividend amount is $6.38 per share.
How sustainable is ABBV's dividend?
Abbvie Inc pays a dividend of $6.38 per share, with trailing twelve month earnings of $2.34 per share. This gives a dividend payout ratio of approximately 100.00%. This very high payout ratio could raise concerns about dividend sustainability if earnings decline in the future.

Company Size & Market

Market Cap

$328.74B

Shares Outstanding

1.77B

Book Value/Share

$0.80

Asset Type

Common Stock

What does ABBV's market capitalization tell investors?
Abbvie Inc's market capitalization is $328.74B, which makes it a mega-cap company. Companies of this size are typically industry leaders with established global presence and significant market influence. Within the pharmaceutical preparations industry, this market cap places Abbvie Inc among the largest players in the sector.
What's the significance of ABBV's book value per share?
Abbvie Inc's book value per share is $0.80, while its current market price is $192.84. This gives a price-to-book (P/B) ratio of 239.85. This relatively high P/B ratio indicates investors are willing to pay a significant premium over the accounting value of the company's equity, typically due to strong growth prospects, high returns on equity, or valuable intangible assets not fully reflected on the balance sheet. In the pharmaceutical preparations industry, this P/B ratio should be compared to industry peers for context.
How does the number of outstanding shares affect ABBV investors?
Abbvie Inc has 1.77B outstanding shares. The number of outstanding shares directly affects metrics like earnings per share (EPS) and can be influenced by corporate actions such as stock splits, buybacks, or new share issuances. With a market cap of $328.74B, each share represents ownership of approximately $186.11 of the company's total value. When companies reduce their outstanding shares through buyback programs, this can increase EPS and potentially support higher share prices, assuming other factors remain constant. Conversely, when new shares are issued, this can dilute existing shareholders' ownership stakes.

Analyst Ratings

Analyst Target Price

$209.61

8.70% upside potential

Analyst Recommendations

Strong Buy

4

Buy

13

Hold

11

Sell

0

Strong Sell

0

How should I interpret analysts' recommendations for ABBV?
For Abbvie Inc, analysts have provided the following recommendations: 4 Strong Buy, 13 Buy, 11 Hold,00 Analyst recommendations reflect professional opinions about a stock's potential performance, but they should be just one factor in your investment decisions. Each analyst may use different methodologies and timeframes for their assessments. Overall, analysts currently have a positive view on this stock.
What does the analyst target price mean for ABBV?
The consensus analyst target price for Abbvie Inc is $209.61, compared to its current price of $192.84. This represents a potential upside of 8.70%. Analyst target prices typically reflect where professionals expect the stock price to be in 12 months. This consensus target is derived from individual price targets set by various analysts covering the stock, and it may be updated as market conditions change or as new information becomes available. Keep in mind that while target prices provide insight into professional expectations, they are not guarantees, and actual price performance can vary significantly from these targets.
How accurate are analyst forecasts for stocks like ABBV?
Analyst forecasts, while informative, have inherent limitations in their accuracy. Studies have shown that analysts' predictions can be influenced by various biases, including optimism bias (tendency to be overly positive) and herding behavior (following other analysts' opinions). In the pharmaceutical preparations industry, forecasts may be particularly challenging due to factors like changing market conditions, competitive dynamics, regulatory changes, and macroeconomic shifts.
Historically, analysts have been more accurate when forecasting:
  • Stable, mature companies with predictable earnings
  • Near-term results rather than long-term performance
  • Companies with transparent business models
Consider analyst forecasts as one tool among many in your investment research, and evaluate them alongside other metrics, industry trends, and your own assessment of the company's fundamentals and market position.

Fundamentals last updated: Jun 2, 2025, 08:33 AM

Technical Indicators

RSI (14-day)

52.23

Neutral

50-Day Moving Average

$186.57

3.36% above MA-50

200-Day Moving Average

$186.42

3.44% above MA-200

MACD Line

-0.23

MACD Signal

-0.79

MACD Histogram

0.56

Bullish

What does ABBV's RSI value tell investors?
Abbvie Inc's current Relative Strength Index (RSI) is 52.23. This indicates neutral momentum as the RSI is in the middle range. Values around 50 suggest no clear directional bias. The RSI is a momentum oscillator that measures the speed and change of price movements on a scale from 0 to 100. It's used to identify overbought or oversold conditions and potential reversals.
How should I interpret ABBV's moving averages?
Abbvie Inc's current price of $192.84 is above both its 50-day moving average ($186.57) and its 200-day moving average ($186.42). This is typically considered bullish, indicating the stock is in an uptrend across both short and long-term timeframes. Additionally, the 50-day moving average is above the 200-day moving average, forming what traders call a 'golden cross,' which is generally considered a bullish signal. Moving averages smooth out price data to create a single flowing line, making it easier to identify the direction of the trend. The 50-day MA represents medium-term trend, while the 200-day MA reflects the long-term trend.
What is the MACD indicating about ABBV's momentum?
For Abbvie Inc, the MACD Line is -0.23, the Signal Line is -0.79, and the MACD Histogram is 0.56. The positive MACD histogram indicates bullish momentum, with the MACD line above the signal line. This suggests buying pressure is currently stronger than selling pressure. The MACD (Moving Average Convergence Divergence) is a trend-following momentum indicator that shows the relationship between two moving averages of a security's price. The MACD line is calculated by subtracting the 26-period EMA from the 12-period EMA. The signal line is a 9-period EMA of the MACD line, and the histogram represents the difference between the MACD line and the signal line.

Indicators last updated: Jun 5, 2025, 12:46 AM

Active Alerts

Alert Condition
Reaches new 52-week low
Threshold
N/A
Created
May 17, 2025, 02:09 PM
Alert Condition
Price rises above
Threshold
$200.00
Created
May 17, 2025, 02:01 PM

Stay Ahead of the Market with Abbvie Inc Alerts

Set up price alerts for Abbvie Inc and get notified instantly when the price hits your target. Never miss an important price movement again.